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Multiple-drug-resistant tuberculosis (MDRTB) is more difficult to treat and the treatment is less likely to produce 
favourable results compared to treatment of drug-sensitive disease. Success requires close co-operation between the 
laboratory, which defines a case as MDRTB, and the clinical team, who will treat it as well as the public health staff 
who will address aspects of contact tracing and institutional cross-infection. National surveys have indicated that 
MDRTB occurs at a higher rate in some countries such as Estonia and Latvia (14.1% and 9% respectively, in 1998) 
and Russia (although there are only limited validated data). In contrast, in Western Europe and in some countries 
of Eastern Europe, such as the Czech Republic, Slovenia, Slovakia and Poland with good tuberculosis (TB) 
prevention and treatment programmes, the combined MDRTB prevalence was 1% or less. 
The early diagnosis of MDRTB and case management by experienced teams from the outset remains the best hope 
clinically for these patients. Adequately supervised and prolonged combination chemotherapy is essential, with drug 
choice governed mainly by quality-controlled in vitro drug susceptibility data.There is a more limited role for surgery, 
and immunomodulating therapy, such as the use of gamma-interferon, may have a useful adjunct role. Clearly the 
most important therapeutic modality for MDRTB is to treat drug-sensitive TB correctly in the first instance and 
prevent the emergence of resistant TB. 
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EPIDEMIOLOGY OF TUBERCULOSIS 
Most cases of clinical TB occur in the developing world, 
with approximately 5% of cases occurring in the 
developed world.re3 Even in industrialized countries, 
such as those of Western Europe, cases have increased 
steadily over the last decade (Figure 1). One-third of the 
world’s population is infected by the bacterium Myco- 
bacterium tuberculosis, which causes TB, with approxi- 
mately 10% of infected individuals developing clinical 
illness during their lifetime; 8 million new cases with 2 
million deaths occur each year.2,3 
Most industrialized countries saw an increase in 
cases from the end of the 1980s and in most states there 
has been an asymmetrical geographical distribution of 
cases within the country. Even in countries with low 
incidence, such as England and Wales for example, cases 
have increased steadily since the end of the 1980s so that 
in 1998 there were 5658 TB cases, giving an annual rate 
of 10.9/100,000, which is an 11% increase compared to 
the results obtained in the 1993 survey (Figure 2).4 
Within low-incidence countries there may be ‘hot spots’ 
of higher TB incidence and drug resistance such as 
London in England, which saw case numbers dramatic- 
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ally increase during the same period (an increase of 
71%). Annual rates of TB continued to decline among 
the white population (4.4) and in those from the Indian 
subcontinent although the rate was still high (121), but 
increased in all other ethnic groups especially among 
Black Africans (210). Nearly 56% of cases were in those 
born abroad.5,6 
The situation has continued to deteriorate; 6,797 
cases were reported in 2000, approximately 10.6% 
higher than for 1999 (6,144 cases), again with two-thirds 
of the increase accounted for by cases in London.7 
Although TB can affect any organ in the human 
body, of concern for public health is the increase in 
pulmonary cases, in which the bacterium appears in 
expectorated sputum, so-called ‘smear positive cases’. 
The proportion of smear-positive pulmonary cases is an 
important and valuable indicator in any TB programme 
reflecting both the quality of diagnostic services and 
access to medical care. 
Further discussion on the epidemiology of TB is 
outside the scope of this article and has been reviewed 
elsewhere.r”Jj 
Epidemiology of drug-resistant cases 
Drug-resistant cases of tuberculosis occur as a result of 
‘treatment non-compliance’: lack of adherence to 
therapy; poor medical or nursing practice in which 
incorrect treatment regimens are prescribed; or, less 
commonly, because of physiological problems, such as 
drug interaction or malabsorption. Multiple drug- 
resistant tuberculosis (MDRTB) is defined as clinical TB 
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Figure 1. Rates of tuberculosis infection in Western European countries (per 100,000 population). 
in which the isolated bacteria are resistant to both 
isoniazid and rifampicin (plus any other drugs). Drug 
resistance may be acquired during therapy or may arise 
de novo when an individual is infected by drug-resistant 
bacteria (primary).1,8-10 
There have been excellent single-country surveys of 
drug resistance in developed and developing countrieslo 
but few countries have developed a programme of 
either regular surveys or continuous surveillance. Data 
from drug-resistance surveys and surveillance conducted 
as part of the World Health Organisation (WHO) and 
International Union Against Tuberculosis and Lung 
Disease (IUATLD) have attempted to quantify the level 
of drug resistance internationally.9 
MDRTB-THE EXTENT OF THE PROBLEM 
In most Western European countries the median 
combined prevalence for MDRTB was low, at approxi- 
mately 1% of all cases of TB. The United Kingdom 
is a good example of a low-incidence country with 
continuous surveillance for drug resistance. Data from 
the seven national and regional centres performing drug 
susceptibility testing (DST) is collated annually. In 1999, 
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Figure 2. Tuberculosis: notifications and deaths in England & Wales 1981-1998. 
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5.9% of TB cases had primary or initial isoniazid drug 
resistance, 0.9% were rifampicin resistant and 0.8% 
were MDRTB,10,11,12 (Table 3). 
Some countries in Eastern Europe were found to 
have high levels of MDRTB; for example, in Latvia and 
Estonia 14.4% and 11.7% of initial isolates were 
MDRTB respectively. Other former member countries 
of the USSR are believed to have high rates of drug 
resistance and Russia is described in detail as an 
example of such a country (see below). Other countries 
in Eastern Europe with a well developed TB prevention 
and treatment programme, such as Slovenia, Slovakia, 
the Czech Republic and Poland have a prevalence of 
MDRTB similar to that of Western Europe (1% or less)? 
There are scant data from Asia. The magnitude of 
the MDRTB problem from countries such as India, 
Pakistan, Bangladesh and China, which account for a 
substantial proportion of the world’s TB cases, remains 
unclear. 
The epidemiology of TB in Russia 
In contrast to the UK, Russia is believed to have high 
rates of drug resistance and MDRTB, although in most 
cases studies in accordance with WHO/IUATLD 
principles have been few and data have been extra- 
polated from them to produce a national picture.13 
Despite methodological problems regarding labora- 
tory methodology and potential bias in the selection of 
M. tuberculosis isolates for analysisI recent data from 
the Russian Federation Federal TB institutes paint 
a gloomy picture. 13-15 There are differences in case 
definition and methodology; for example, a major tool 
used for TB control is widespread screening by fluoro- 
graphy based on the concept that radiological methods 
detect TB at an earlier stage of disease than those using 
smear microscopy. Annual fluorographic screening 
continues to be compulsory for every citizen, together 
with a high coverage immunisation programme (Bacille 
Calmette-Guerin [BCG]), which includes multiple 
vaccinations?J7 
In common with Western Europe,TB rates declined 
from the 1950s to the 1990s and the lowest incidence 
and mortality rates occurred in 1991 (34.0/100,000 and 
8.1/100,000, respectively). From 1991 to 1999, the 
notification rate for new TB cases increased by 7.5% per 
annum and the death rate by 11%.15 In 1999, approxi- 
mately 120,000 new cases15 were recorded, and in the 
year 2000 new case rate notification, including prisoners, 
the homeless and non-residents was 90.7/100,000 
(132,000 cases). The mortality rate increased by 29.9% 
from 1998 to 1999 (1999: 20.0/100,000 population, 29,078 
TB patients died).14Js 
Information on drug resistance has only recently 
been incorporated into national figures. Rates of TB 
should be interpreted with caution as comparisons are 
complicated by differences in case definitions (e.g. a ‘new 
case’) and diseases and treatment classifications differ 
from internationally accepted WHO diagnosis and cure 
criteria. Data have traditionally been compiled from two 
different statistical forms-one that covers permanent 
residents only and another that includes prisoners and 
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Figure 3. Trend analysis of drug resistance in the UK 1994-1999 (Mycobnet). 
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homeless patients. The figures from these forms are 
significantly different and much higher in the latter case 
because prisoners form a major group of TB patients. 
Although treatment remains based on guidelines 
(federal or local) an ‘individual approach principle’ is 
practised where a physician bases decisions on TB 
drugs and duration of treatment with administration of 
surgery, ‘physiotherapy’ and adjunct therapies on 
personal clinical experience. The choice of second-line 
drugs is also influenced by the availability of given drugs. 
In contrast, international protocols for drug-sensitive TB 
are highly standardized, permitting only minimal 
deviation from prescribed practice. 
Drug-resistant TB in Russia 
Since 1999, data on MDRTB in new cases have been 
added to official state statistics, although not all the 
regions submit accurate figures. Multiple-drug-resistant 
tuberculosis was detected in 2.9% of all new cases 
and in 7.1% of smear and/or culture positive cases.14 
MDRTB data vary greatly from region to region. Rates 
of MDRTB are difficult to estimate based on existing 
data. In order to define the scale of the problem more 
precisely, studies are being conducted in a small number 
of oblasts or regions within Russia that demonstrate the 
features associated with drug resistance elsewhere. 
One such region is Samara, where a detailed drug 
resistance survey is being carried out across the civilian 
and penitentiary sectors to establish whether resistance 
is acquired and what the underlying epidemiological risk 
factors for development of drug-resistant TB are. This 
includes baseline quality control assessments for 
microscopy, culture and DST, and includes a molecular 
epidemiology analysis across all sectors of the region. 
Diagnostic services are being improved as part of the 
joint collaborative effort including laboratory design 
and construction. The role of molecular diagnostic 
methods to detect MDRTB isolates will be investigated. 
This collaborative project funded by the UK 
Department for International Development and imple- 
mented by the UK Public Health Laboratory Service 
Mycobacterium Reference Unit revealed during its the 
pilot phase some of the probable complications that 
prevent international comparisons of data. These 
include: blurring of the distinction between new cases 
and long-term treatment cases resulting from either 
failed therapy or patient non-compliance; chronic case 
and relapse cases may be interchangeable in practice; 
laboratory techniques vary greatly, not only across the 
country but even across the region or the town, with 
laboratories using standard protocols in theory but often 
with personal modifications. There is a need for a well- 
developed quality control strategy, particularly in the 
area of drug-susceptibility testing. Bacteriologists are 
not involved in a patient’s treatment and laboratory 
staff, performing culture and DST, are usually not aware 
of microscopy results. Drugs for treatment of tubercu- 
losis, as well as most other antibiotics, are available over 
the counter without prescription and are sometimes 
used for treatment of other conditions, acting as a driver 
for drug resistance. 
Samara has one of the highest living standards in the 
Russian Federation, nevertheless in 1999 and 2000 the 
new case rates for TB were 85.41/100,000 (2,813 cases) 
and 87.6/100,000 (2,890 cases), respectively, in a 
population of 3,308,OOO (including non-residents and 
prisoners. Among registered residents of the region and 
the city the rates were lower at 61.8/100,000 (2,035 
cases) in 1999 and 61.5/100,000 (2,890 cases) in 2000 in 
the region, and 56.7/100,000 (1,391 cases) in 1999 and 
57.1/100,000 (2,114 cases) in 2000, in the city. Mortality 
in the region in 2000 was 13.6.0/100,000 (443 cases). 
Smear and culture positivity was seen in 863 and 672 of 
new cases only (26.4/100,000 and 27.6/100,000) within 
the region and the city, respectively. At the moment, as 
a result of increasing numbers of intravenous drug users 
in the region the problem of HIV infection is increasing 
(over 10,000 HIV-infected individuals were registered in 
Samara Region in May, 2001). Accordingly the number 
of patients dually infected by TB and HIV is slowly 
increasing.17 
Tuberculosis is a major problem in Samaran prisons 
(as in the whole of Russia), l8 where the total number of 
TB patients at the present time is 1,800 cases (-34% of 
all registered TB patients in the region). There remains 
a high loss of follow-up of former prisoners after release, 
leading to partial therapy-a problem across the 
Russian Federation. Severely ill prisoners in the Russian 
Federation receive a social allowance related to a 
‘disability group’ and prisoners with TB are kept at a TB 
prison hospital with better food and conditions than in 
a regular prison and without the requirement to perform 
hard labour. Serious illness is also frequently one of 
the indicators for amnesty and release. All these factors 
create incentives for prisoners to remain ill for as long 
as possible and treatment adherence becomes a problem. 
Unfortunately in most cases smear-positive and smear- 
negative individuals with resistance to anti-TB drugs 
cannot be isolated from patients without resistance. 
DIAGNOSIS OF MDRTB 
The diagnosis of MDRTB is fundamentally made in the 
laboratory. Clinical failure to improve on therapy is not 
proof of drug resistance but should be one of the reasons 
to aim for accurate measurement of drug resistance of 
bacterial isolates derived from patients where drug- 
resistance analysis would not normally be routinely 
conducted. The laboratory plays a central role in the 
definition of MDRTB through the application of quality- 
assured bacteriological and/or molecular methods for 
DST employed on cultures or primary specimens from 
the patient. 
Any microbiological DST service should be 
rigorously quality-controlled through internal and 
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external mechanisms. The latter through national 
centres and subsequently through supranational systems 
such as that developed by the WHO and IUATLD. The 
analysis of drug resistance is traditionally made pheno- 
typically by measuring an outcome such as death of 
M. tuberculosis when grown on solid or liquid antibiotic 
drug containing culture media. Improvements in auto- 
mation and liquid culture have reduced the prolonged 
incubation times required for interpretable results using 
solid culture media but this has led to higher test costs 
and has increased the potential danger to laboratory 
staff by working with liquid cultures. Novel phenotypic 
methods, including the use of mycobacteriophages 
(viruses that parasitize M. tubercuZosis)1g-23 and dyes 
such as Alamar Blue,24 have been developed with some 
success. 
Molecular nucleic acid-based methods, primarily 
focused on the measurement of rifampicin resistance 
(genotypic),‘have revolutionized this area of diagnosis, 
producing reproducible results directly from smear- 
positive specimens within 1-3 days. All require some 
form of preliminary amplification of either DNA or 
RNA, followed by detection of gene mutations using 
direct sequencing or mutation detection by DNA 
hybridization in solid-phase systems in manual or costly 
DNA ‘chip’ formats. These methods have been reviewed 
elsewhere.25-28 
Methods employing the short-lived mRNA have 
been useful both for measuring viability and analysing 
drug resistance. 22,23,29 For any amplification-based assay 
to be employed successfully careful attention to speci- 
men handling, sample preparation and the prevention of 
cross-contamination are essential and, as Roth et al. say, 
“ . . . the current uncritical neglect of these stringent 
requirements has led to the widely held, but mistaken, 
belief that clinical amplification tests are simple to 
perform and can easily be introduced in any normally 
equipped microbiology laboratory”.30 
In conclusion, to quote from the WHO guidelines 
for the management of drug-resistant tuberculosis, “the 
specialized [TB] unit must have the services of a 
laboratory able to carry out culture and reliable tests for 
drug resistance (to the essential drugs and also to 
second-line drugs).The quality of the susceptibility tests 
carried out in this laboratory should be regularly 
checked by another’reference laboratory at national or 
supra-national level.“31 
WHY DOES MDRTB OCCUR? 
Drug resistance develops spontaneously in bacteria and 
combinations of drugs are used to nullify this clinically 
significant resistance, and to make treatment failure 
unlikely. 
Arguably the most important factor associated with 
drug resistance is prior treatment. In the recent analysis 
of national drug resistance trends in the USA, for 
example, resistance rates were significantly higher in 
those who had previously had TB.32 Comparable find- 
ings were seen in the UK. 11,33 Reasons for inadequate 
prior therapy are: failure of the patient to adhere to 
therapy (patient non-compliance); failure to prescribe 
an adequate standard regimen (physician non-compli- 
ance); or problems with malabsorption or drug inter- 
action limiting the efficacy of TB therapy (physiological 
non-compliance). Deterioration of the clinical and 
public health infrastructure needed for adequate super- 
vision of treatment is also linked with the selection of 
drug resistance strains.1,25,31,34-36 
Mahmoudi and Iseman37 examined the records of 
3.5 patients with acquired MDRTB, who were admitted 
to the National Jewish Hospital in Denver, Colorado, 
from other centres, and noted that there were errors in 
clinical management in 28 cases. The most common 
included: addition of a single drug to a failing regimen; 
failure to identify primary drug resistance; inappropriate 
isoniazid chemoprophylaxis; prescription of an inappro- 
priate initial drug regimen; failure to modify the drug 
regimen in light of drug sensitivities; and failure to deal 
with non-compliance. Similar errors are still being made. 
Malabsorption of anti-tuberculous drugs may be of 
importance in some patients, such as those co-infected 
with HIV, for example, in one prospective study of 26 
HIV-positive patients, low serum concentrations were 
seen for rifampicin and ethambutol, in particular, with 
little change in isoniazid levels.38 Drug resistance was 
significantly associated with HIV positivity in the UK 
(although the results were strongly influenced by 
outbreaks of MDRTB) and the USA.11,32,33 The associ- 
ation of TB and HIV has proved to be a major new 
factor in the increase of clinical TB in the developing 
world as well, where even model programmes, such as 
those supported by the IUATLD, have faltered.2,39 
Immigration from high incidence countries may 
explain circumscribed areas of relatively high incidence 
in otherwise low incidence countries, although the over- 
all picture may be complex. In the USA, between 1993 
and 1996, although overall drug resistance was associ- 
ated with foreign birth, MDRTB was not.32 Multiple- 
drug-resistant tuberculosis was associated with foreign 
birth among cases in the UK? 
It is therefore clear that the most important 
preventative measure is to achieve the correct treatment 
of drug-sensitive TB initially, with each new case of 
pulmonary TB receiving an effective regimen of short 
course chemotherapy (6 or 8 months) with four drugs 
(isoniazid, rifampicin, pyrazinamide, ethambutol or 
streptomycin) during at least the first 2 months, given 
under direct observation. 
CLINICAL DISEASE 
Should we treat MDRTB? 
Multiple-drug-resistant tuberculosis is treated in 
countries with sufficient resources for diagnosis and 
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complete treatment of cases which may require pro- 
longed and expensive therapy (see later). On a global 
basis there has been enormous debate as to the merits 
or need for MDRTB treatment.25,40 Until recently, the 
WHO has held to a strategy of directly observed 
therapy, short course (DOTS) for resource-poor coun- 
tries as the most effective mechanism for overall TB 
control. Such a strategy, it is argued, would also prevent 
the emergence of MDRTB by improving compliance, 
case holding and cure rates. 
The rigid application of DOTS alone in areas with 
a high incidence of MDRTB, however, may exacerbate 
the problem, as resistance develops to ethambutol and 
pyrazinamide during the intensive phase of treatment. 
These patients are unlikely to be cured and so a focus of 
broader drug resistance is created. Blind repetition of 
current empirical re-treatment regimens will amplify 
drug resistance further for similar reasons. There is little 
doubt that DOTS prevents the emergence of MDRTB 
but only limited evidence that DOTS can solve an 
established MDRTB problem, particularly in immuno- 
competent individuals. 
A strategy of treatment of MDRTB cases globally 
has been promulgated by the WHO as ‘DOTS Plus’ 
with a key prerequisite that there is a functioning 
DOTS strategy in place beforehand. A planned and 
coherent strategy is essential using observed standard- 
ized therapy for drug-sensitive cases, coupled with a 
tailored approach to MDRTB cases. Nevertheless the 
rate of drug resistance, and particularly MDRTB, must 
be quantified, the reasons for high rates of MDRTB 
established and corrective action taken to address the 
underlying problems first. 
Cost has been the major factor in determining 
whether national TB programmes can afford to treat 
MDRTB cases. Even in wealthy countries the individual 
patient cost has been highlighted; in the UK the cost of 
treatment can be prohibitive, and was calculated to be 
approximately &60,000 ($85,000) per patient.41 
Treatment of MDRTB 
Drug-resistant organisms are selected for by inadequate 
chemotherapy. In the case of MDRTB, sequential 
accumulation of resistance occurs so that most isolates 
are resistant to isoniazid initially and subsequently 
become resistant to rifampicin. In the UK, approximately 
90% of rifampicin-resistant isolates are MDRTB,42 so 
that diagnostically rapid identification of rifampicin 
resistance is predictive of MDRTB.This is true for many 
countries but needs further investigation wherever 
rifampicin is used to treat other medical conditions or 
where antibiotic sales are unrestricted. 
The fundamentals of treatment are unchanged i.e. 
combination chemotherapy but for a longer duration. 
Successful treatment of MDRTB, unlike drug-sensitive 
TB, requires individualized therapy for prolonged 
periods with second- and third-line drugs, ideally using 
drug susceptibility data to determine the drug combin- 
ation. Interestingly, although the Russian belief in the 
need for individual tailoring of treatment for all TB 
cases to suit drug-sensitive cases would be challenged 
elsewhere for drug-sensitive cases, its use in MDRTB 
therapy finds common ground. Patients should be 
treated with at least three agents to which the organism 
is susceptible, including as many bactericidal agents as 
possible. Single agents should never be added to a failing 
regimen. Therapy should be directly observed, using 
appropriate incentives to support compliance. These 
recommendations have been promulgated in local, 
national and international documents.31,42-45 
If we accept that MDRTB should be treated 
wherever it occurs, what is the likelihood of success? 
Patients with drug-resistant TB have lower response 
rates than those with drug-susceptible isolates and 
those with MDRTB have the lowest cure rates. In a 
review of the outcomes of patients with drug-resistant 
TB from 12 controlled trials, of 8,212 patients studied, 
1,041 (12.7%) had TB with initial resistance to one drug; 
256 (3.1%) of cases had resistance to isoniazid and 
streptomycin with only 11 isolates resistant to rifampicin. 
Therapy failed in five out of these 11 cases and three of 
the remaining patients relapsed.46 Recent studies have 
demonstrated that mono-resistance to isoniazid produced 
lower cure rates than expected, despite apparent close 
supervision.47,48 
In a seminal study,49 the outcomes of MDRTB cases 
referred to one institution from 1973-83 were reviewed. 
Patients were infected with isolates resistant to a mean 
of six drugs and treatment failed in 35% of 171 HIV- 
negative patients, as shown by persistently positive 
cultures, despite the use of individually tailored regimens 
by an experienced team. The overall response rate, 
including relapses, was 56%, with mortality attributed to 
MDRTB in 22% of cases. An analysis of outcomes, 
however, in 26 HIV-negative patients in New York City 
with MDRTB indicated that of the 25 individuals for 
whom there was sufficient clinical data, 24 (96%) had a 
clinical response, and in 17 patients for whom there was 
microbiological data, all showed a positive response.50 
The improved response in the New York study in 
comparison to that seen in Denver49 reflects the earlier 
diagnosis of MDRTB, the fewer drugs that the isolates 
were resistant to, the shorter duration of MDRTB (2.5 
years versus 6 for those in Denver) and the lack of 
extensive previous treatment. In a study of 63 pulmon- 
ary MDRTB patients in South Korea, who had previously 
received a mean of five drugs and were shedding bacilli 
resistant to a mean of four drugs (i.e. analogous to the 
Denver patients), 53 (82.5%) responded to therapy as 
indicated by negative sputum cultures for at least three 
consecutive months.51 In the mean follow-up period of 
17 months, there was no subsequent relapse amongst 
patients who responded initially. 
Although MDRTB carries a high mortality in the 
immunocompromised, two New York City studies 
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demonstrated an improved outcome with treatment 
using at least three drugs to which the organism is 
susceptible on in vitro testing.52,53 This reinforced the 
results of an earlier retrospective study at one New York 
institution, in which 38 MDRTB cases were identified, 
of which 34 (89%) were HIV positive. First-line drug 
susceptibilities were reported in a median of 30 days. 
The median survival period in this group was 315 days 
and 50% died directly as a result of MDRTB.53 A larger 
study of 173 MDRTB patients from 1983 to 1994 in New 
York City, in which 52% were known to be infected with 
HIV, demonstrated that mortality was greater in HIV- 
positive patients. Survival, however, regardless of immune 
status, was strongly associated with the early institution 
of appropriate therapy.54 
Good results were obtained from treatment of 
MDRTB patients at a single institution in Turkey.55 
By contrast, the retrospectively analysed outcome 
of a cohort of patients treated at multiple centres in the 
United Kingdom has been less encouraging. Ninety 
MDRTB patients were identified from January 1996 
to June 30 1997. Survival was calculated using a Cox 
proportional hazards model based on the date of 
bacteriological diagnosis until date of death or survival 
on December 1 1998. Sufficient data were available on 
82 patients. Overall, 20/27 patients died of TB and 
median survival was 1379 days (95%CI: 1336,2515) or 
3.78 years (95%CI: 3.66, 6.89 years). In known 
immunocompromised individuals (n=32), survival was 
only 858 days (95%CI: 530, 2515).56 These results 
emphasize what can be achieved by treatment of diffi- 
cult cases by teams with sufficient expertise developed 
through the management of sufficient patients. 
In a recent treatment analysis summarizing the 
findings of several drug resistance surveys, the rapid 
diagnosis of isoniazid and rifampicin resistance were 
found to be important, as expected, but, interestingly, the 
diagnosis of ethambutol and streptomycin resistance 
was of minimal significance.57 This provides support for 
a proposed cost-effective model for the rapid diagnosis 
of isoniazid and rifampicin resistance (and hence 
MDRTB) .58 
Measurement of outcome 
Clearly, if treatment outcomes are to be compared for 
MDRTB, there is a need to accept a set of criteria for 
cure or ‘success’. Microbiological improvement has a 
worldwide role in measuring treatment success but the 
emphasis and its importance within a group of criteria 
differ. In Russia, for example, positive treatment out- 
comes for new TB cases are assessed based on two 
major criteria: culture negativity and cavity closure. 
There is extensive follow-up post-treatment (according 
to ‘dispensary groups’), with courses of anti-relapse 
post-treatment chemoprophylaxis given in accordance 
with the seasons (e.g. spring16). In cases of successful 
treatment, a patient pronounced clinically cured (usually 
after 2 years of main treatment courses and at least 
1 year of anti-relapse therapy) is followed up the for 
next 10 years. Patients with cavities are considered to be 
potentially infectious and remain under observation and 
treatment for significantly longer periods. Clearly this 
combination of criteria may be too stringent, but long- 
term follow-up of MDRTB cases is essential to monitor 
true outcome and clinical effectiveness. 
NOVEL THERAPIES 
New chemotherapy 
There has been little real development in new chemo- 
therapeutic classes, although there have been some 
advances in the development of agents within existing 
drug classes (rifamycins such as rifabutin, rifapentine 
and benxoxazinorifamycin; macrolides, fluoroquino- 
lones and immunomodulating drugs). Promising in vitro 
and in vivo animal data for rifapentine59 led to clinical 
trials with mixed results;‘jO,‘jl for example, 71 HIV- 
positive patients in US Public Health Service Study 2260 
with culture-positive drug susceptible TB, who com- 
pleted 2 months of four-drug therapy (isoniazid, 
rifampicin, ethambutol, pyrazinamide), were randomly 
assigned 900 mg isoniazid and 600 mg rifampicin twice 
weekly or 900 mg isoniazid and 600 mg rifapentine once 
weekly. Five of 30 patients in the once-weekly arm 
relapsed, compared with three of 31 patients in the 
twice-weekly group; four of the five relapse cases had 
monoresistance to rifamycin compared to none of the 
three cases in the twice-weekly group. Results in 
the HIV-negative group, however, have been more 
promising. Similarly, early results for benoxazino- 
rifamycin are encouraging.62 
Table 1 summarizes the main properties of the 
different chemotherapeutic groups available for treat- 
ment of MDRTB. Improvements in the delivery of 
established agents, such as liposomal encapsulation of 
drugs, have been made. Development of novel four-drug 
fixed dose combination drugs with good bioavailability 
should facilitate the prevention of MDRTB by 
improving treatment delivery for drug-sensitive and 
monoresistant disease rather than MDRTB manage- 
ment. Experimental work such as the use of depot 
polymer-containing isoniazid preparations in animals 
may find value in human treatment in the future.63 
Although fluoroquinolones with improved serum 
concentrations have been developed, there is little 
evidence of greater clinical improvement or survival. 
Publication of the complete DNA sequence of the 
genome of 44. tubercuZosis64 (with a clinical isolate and 
M. bovis virtually complete) and the identification of 
critical and specific metabolic pathways offers hope for 
the development of new agents. This will require radical 
new thinking into the economics of drug development if 
any promising candidates are to reach the patient. 
S28 International Journal of Infectious Diseases I Volume 6, Supplement 1,2002 
Table 1. Properties of key chemotherapeutic agents used in the management of MDRTB cases 
Drug Notes 
Rifabutin 
Rifapentene 
Benxoxazino-rifamycin 
Clarithromycin 
and azithromycin 
Ciprofloxacin 
Effective against a small proportion of isolates resistant to rifampicin 
Long half-life, permitting weekly or twice-weekly dosing; recent Hong Kong study using Chinese- 
manufactured drug showed high relapse rates as a result of its low bioavailability; further USA and 
South African trials with improved formulation, although initial USA results showed high relapse with 
rifampicin monoresistant isolates 
Rifamycin with lower MIC in vitro than either rifampicin or rifabutin but exhibits cross resistance with 
rifampicin 
Novel macrolides; only modest activity against TB; main use is to prevent the emergence of 
resistance to other drugs when used in combination with them 
Bactericidal; other fluoroquinolones such as ofloxacin, levofloxacin and sparfloxacin achieve higher 
serum levels 
Amikacin Most clinical data for the use of streptomycin; some streptomycin-resistant isolates remain amikacin- 
sensitive; liposomal encapsulation in vitro and in experimental animals has better delivery and activity 
against MTB than the free agent because of increased macrophage uptake 
MIC, minimum inhibitory concentration; MTB, mycobacterium tuberculosis 
Immunotherapy 
Immunotherapy remains largely experimental but is 
likely to be of greatest potential in the treatment of 
MDRTB cases. Trials of M. vaccae as an immuno- 
therapeutic adjunct to chemotherapy have had mixed 
success.65,66 
Cytokine therapy is possible, but whereas some 
cytokines can inhibit mycobacterial growth (interleukin 
[IL]2, IL12, tumour necrosis factor, interferon [IFN], 
granulocyte-monocyte colony stimulating factor [GM- 
CSF], 1,25-dideoxycholecalciferol), they can also pro- 
mote mycobacterial growth (IL4, ILlO) and their effects 
may differ, depending on their concentration or route by 
which they are administered.67-70 The most studied 
cytokine, biologically and clinically, has been gamma- 
interferon (IFN); its key properties are indicated in 
Table 2. In mice, administration of gamma-IFN poten- 
Table 2. Effects of immunotherapy with cytokines in general, 
and gamma-interferon in particular 
Cytokines 
Can inhibit mycobacterial growth (IL2, ILIZ, TNF, IFN, GM-CSF, 
1,25-D3) 
Can promote mycobacterial growth (IL4, ILIO) 
Increase or decrease immune activity 
Are expensive but complex and potentially dangerous 
Gamma-interferon (IFN) 
Glycoproteins 40-70 kDa 
Produced by CD4, CD& NK cells 
Major immune activator 
Induces expression of MHC class II molecules 
Primes macrophage to release IL1 
Activates macrophages for phagocytosis 
Stimulates production-reactive nitrogen species, mainly via NO 
synthase 
Augments antigen presentation 
Increases responsiveness to IL2 
IL, interleukin; TNF, tumour necrosis factor; IFN, interferon, GM-CSF, ; 
1,25-D3, 1,25-dideoxycholecalciferol; CD, ; NK, natural killer; MHC, major 
histocompatibility complex; NO, nitrogen oxide. 
tiates macrophage killing of mycobacterium tubercu- 
losis [MTB] and in gamma-IFN gene-knockout mice 
sublethal bacterial doses kill the mice.64@,67 IL12 given 
with MTB to BALB/c mice doubled the survival time 
from 58 to 112 days when compared to mice inoculated 
without IL12.67 
There are published few data on the clinical use of 
immunomodulating cytokines in refractory TB. Follow- 
ing a preliminary report, 69 there has been one small 
open label study in which five MDRTB smear- and 
culture-positive patients were given chemotherapy with 
aerosolized gamma-IFN and some symptomatic improve- 
ment was seen.71 An alternative approach has been to 
antagonize the production of tumour necrosis factor 
alpha using thalidomide, which resulted in modest 
clinical improvement.72 
Surgery 
The place of surgery in the management of TB is one of 
the major differences between treatment in the ‘western’ 
world and those countries of the former USSR, where 
surgical treatment is still commonplace.16 For MDRTB, 
however, there is increasingly a greater concordance of 
view that surgery is effective, although, ironically, there 
is a relative lack of experience in surgical management 
in the ‘west’ compared to the ‘east’. Medical manage- 
ment is still the principal therapeutic modality in all 
cases but there is a role for additional surgery in those 
MDRTB cases where pulmonary disease is localized and 
where there is sufficient cardiopulmonary reserve.73,74 
CONCLUSION 
The early diagnosis of MDRTB and case management 
by experienced teams remains the best hope clinically 
for these patients. Adequately supervized and prolonged 
combination chemotherapy is essential, with drug choice 
governed mainly by quality-controlled in vitro drug 
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susceptibility data. Surgery and immunomodulating 
therapy may have a useful adjunct role. Results from 
clinical studies suggest that rapid diagnosis of MDRTB 
and management of cases by dedicated experienced 
teams from the outset are likely to lead to improved 
survival. 
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